ARGENX SE-ADR (NASDAQ:ARGX) has been given a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.

Brokers have set a 12 month consensus price target of $36.33 for the company, according to Zacks. Zacks has also given ARGENX SE-ADR an industry rank of 110 out of 265 based on the ratings given to its competitors.

A number of analysts have recently weighed in on the company. Wedbush reissued an “outperform” rating and issued a $41.00 price objective (up previously from $26.00) on shares of ARGENX SE-ADR in a research report on Thursday, November 16th. They noted that the move was a valuation call. Zacks Investment Research raised ARGENX SE-ADR from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a research report on Tuesday, October 31st. Finally, Cowen and Company reissued a “buy” rating on shares of ARGENX SE-ADR in a research report on Thursday, August 24th.

ARGENX SE-ADR (NASDAQ ARGX) traded up $0.42 during trading on Friday, hitting $25.00. The stock had a trading volume of 121,700 shares, compared to its average volume of 30,301. ARGENX SE-ADR has a 52-week low of $17.33 and a 52-week high of $27.25.

A number of institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC acquired a new stake in ARGENX SE-ADR during the 2nd quarter worth about $15,990,000. VHCP Management II LLC acquired a new stake in ARGENX SE-ADR during the 2nd quarter worth about $13,615,000. Pictet Asset Management Ltd. acquired a new stake in ARGENX SE-ADR during the 3rd quarter worth about $11,812,000. Federated Investors Inc. PA acquired a new stake in ARGENX SE-ADR during the 2nd quarter worth about $9,545,000. Finally, Franklin Resources Inc. acquired a new stake in ARGENX SE-ADR during the 2nd quarter worth about $7,424,000. 24.68% of the stock is owned by institutional investors.

WARNING: “ARGENX SE-ADR (ARGX) Receives Average Recommendation of “Strong Buy” from Brokerages” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/22/argenx-se-adr-argx-receives-average-recommendation-of-strong-buy-from-brokerages.html.

About ARGENX SE-ADR

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Get a free copy of the Zacks research report on ARGENX SE-ADR (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for ARGENX SE-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARGENX SE-ADR and related stocks with our FREE daily email newsletter.